Context. Etavopivat (Forma Therapeutics) is an oral erythrocyte pyruvate kinase activator being developed for sickle cell diseaseand other hemoglobinopathies, previously reported in 2019. Hydroxyurea had been the only approved…
white
Drug Hunter
Drug Hunter
Context. Etavopivat (Forma Therapeutics) is an oral erythrocyte pyruvate kinase activator being developed for sickle cell diseaseand other hemoglobinopathies, previously reported in 2019. Hydroxyurea had been the only approved…